Drugs / Neural Stem Cell-Derived Exosomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07554872 | May 2026 → Oct 2027 expected | Alzheimer disease | Shanghai Mental Health Center | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neural Stem Cell-Derived Exosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07554872 ↗ |
| Known as | NSC-EVs | “neural stem cell-derived exosomes (NSC-EVs) are considered a promising therapeutic approach” NCT07554872 ↗ |
| Modality | Other / unclassified | “neural stem cell-derived exosome preparation” NCT07554872 ↗ |
| Route | Intranasal | “administered intranasally” NCT07554872 ↗ |